12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Egrifta tesamorelin regulatory update

Theratechnologies said it submitted to Health Canada a request for reconsideration of the agency's notice of non-compliance-withdrawal for an NDS for Egrifta tesamorelin to treat excess abdominal fat in HIV-infected patients with lipodystrophy....

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >